Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (23754)	7/31/1998 12:51:00 PM
From: growthvalue	Read Replies (1) \| Respond to of 32384

The ISIP comparison is 100% valid. This supposed "validation of technology" is nonsense and it's not going to move the stock. I made this comparison on the ISIP thread on Yahoo, but when it was discovered that monoclonal antibodies could be effective in treating disease, does that mean that any company working on MAbs immediately deserved a higher stock price? Why not? The technology had been validated!! The market doesn't care HOW it works, the market wants to know that it DOES work and is going to sell. That's why the market doesn't care about the quality of LGND's science (this is not to say that it is not important). Too many seemingly promising products have failed in phase III for the market to have ANY faith in a company until they bring home some statistically significant results with a product that has big potential. Look at IMNX and AGPH. They had their big moves when they completed phase III. (Generally speaking, if you get two substantially statistically significant phase III results, approval is a no brainer - which is why AGPH moved up before approval, and IMNX has been up before the FDA meeting). LGND needs statistically significant late-phase results in type II diabetes and/or the market has to believe that Targretin oral has the potential to be a Gemzar or even a Taxol (which I think it does). But that may not be soon. Best regards.